pSG.SS.Flk-1ECD.C3d3.YL

pSG.SS.Flk-1ECD.C3d3.YL is an experimental DNA vaccine designed for anti-angiogenic cancer immunotherapy. The vaccine consists of a recombinant plasmid encoding the extracellular domain (ECD) of Flk-1 (the murine homolog of Vascular Endothelial Growth Factor Receptor 2, or VEGFR2) fused to three copies of the complement component C3d (C3d3). C3d serves as a molecular adjuvant that bridges innate and adaptive immunity by binding to complement receptor 2 (CR2/CD21) on B cells, thereby significantly enhancing the antibody response against the Flk-1 antigen. By inducing high titers of Flk-1-specific antibodies, the vaccine aims to inhibit VEGF-mediated signaling in vascular endothelial cells, leading to the suppression of tumor angiogenesis and the inhibition of solid tumor growth, as demonstrated in preclinical models of bladder transitional cell carcinoma.

Other names

Flk-1/C3d3 DNA vaccineVEGFR2/C3d3 DNA vaccine